{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/bites-human-animal/prescribing-information/co-trimoxazole/","result":{"pageContext":{"chapter":{"id":"a0c8184c-9c4d-5943-9d34-6471f2fe8744","slug":"co-trimoxazole","fullItemName":"Co-trimoxazole","depth":2,"htmlHeader":"<!-- begin field 411b5de7-b703-48d0-81d5-a877009ae11c --><h2>Co-trimoxazole</h2><!-- end field 411b5de7-b703-48d0-81d5-a877009ae11c -->","summary":"","htmlStringContent":"<!-- begin item fba5026a-104b-4a4e-bb34-a877009ad9ce --><!-- end item fba5026a-104b-4a4e-bb34-a877009ad9ce -->","topic":{"id":"66885481-1c78-50d7-bd40-cee6daf3a22b","topicId":"1f9ba5f4-d4ca-402b-857f-1ef0227e6eaa","topicName":"Bites - human and animal","slug":"bites-human-animal","lastRevised":"Last revised in October 2020","chapters":[{"id":"4d7c4615-e565-58f7-ab3f-9af67d5fa066","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"d9aea4af-b77b-548e-a62d-b1b69d689e70","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"b16f539f-9832-520a-b08e-b9870416e2ef","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"814b9650-9309-581c-ad8b-77bd0f59d573","slug":"changes","fullItemName":"Changes"},{"id":"451e8923-57cf-55b9-88b6-7767cf1870b3","slug":"update","fullItemName":"Update"}]},{"id":"4f4d63cd-fedc-53a6-9963-001d4f253f2c","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8bb57dc0-b6ce-5ebb-a31d-25b2d527ed6c","slug":"goals","fullItemName":"Goals"},{"id":"51f172a3-e955-5bda-98c3-61a0bd719f16","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"150a707d-3a0a-5115-b633-9ab844daab23","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"77f07ad2-c9ad-5bc2-9b81-5c305f9e8ca3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"51c4f343-6ac9-549d-a068-43084108f8c5","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"909ff9e5-d816-5a1a-a545-0b5d010352f0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"601e2fbe-0e18-597e-9476-633c9f4ef7b3","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a5c3cdd6-9531-5a6c-b1bc-a6e8d12b2307","slug":"definition","fullItemName":"Definition"},{"id":"2158dea0-437f-5805-9e65-e1c277e52475","slug":"characteristics-of-different-types-of-bites","fullItemName":"Characteristics of different types of bites"},{"id":"dcc5a332-7954-5ea2-88e1-7093a2c27960","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d2e33eaa-035d-54f9-b1e6-ee9d3c605297","slug":"complications","fullItemName":"Complications"},{"id":"f9c4fd96-ca8a-53ba-bb96-fe24ea11c8be","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"27cd943b-33a7-5304-8c4f-0f2da1c77fb9","fullItemName":"Management","slug":"management","subChapters":[{"id":"4a38ec65-3aac-5dff-b0e6-ce328b564e2d","slug":"managing-a-human-bite","fullItemName":"Scenario: Managing a human bite"},{"id":"3998b5bd-33dc-52ed-848d-b1c3b6d01573","slug":"managing-a-cat-or-dog-bite","fullItemName":"Scenario: Managing a cat or dog bite"}]},{"id":"cc488aaa-0221-5616-92c9-e9b9a28c206a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a0c8184c-9c4d-5943-9d34-6471f2fe8744","slug":"co-trimoxazole","fullItemName":"Co-trimoxazole"},{"id":"0e041b11-cf29-519b-99be-1751ece6b17e","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"7398d7dd-8a7d-5695-b963-bba32a0445a8","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"696d5b30-ff2f-5b72-875c-03cf5db390c0","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"6410092b-90ae-58a9-8065-103199eca1cb","slug":"paracetamol-ibuprofen","fullItemName":"Paracetamol and ibuprofen"}]},{"id":"703fd48e-b059-5fac-8aef-986c90ceca15","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"869edd83-cb34-55d6-9d47-6931a23adf4e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8e9f1883-896e-54dd-8156-ae8a2aa744d1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3edab9d3-1d3a-5e9d-b8df-83d2ffc14bf0","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"8e969da1-bdae-5ba7-9471-72cff35d2dac","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e8d0ba91-234c-5494-a990-bbe559b68c05","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0e2e4ab4-ad2f-5ad9-a9c6-3d59693be83c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"bdc0f3ee-0644-5a81-b04b-3f1ae3e4310b","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"cc488aaa-0221-5616-92c9-e9b9a28c206a","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"0c105e82-b55e-54c5-9d68-1422d54fd06d","slug":"dosage","fullItemName":"Dosage","depth":3,"htmlHeader":"<!-- begin field f81f254c-5e7c-45f3-a878-a877009bd3eb --><h3>What dosage of co-trimoxazole should I prescribe?</h3><!-- end field f81f254c-5e7c-45f3-a878-a877009bd3eb -->","summary":"","htmlStringContent":"<!-- begin item 065e82db-dcdc-4e25-ac56-a877009bd180 --><!-- begin field a15e2e76-e74f-4735-a333-a877009bd3eb --><ul><li>For treatment of an infected bite wound, the dosage of oral co-trimoxazole is:<ul><li>6 weeks to 5 months: 120 mg or 24 mg/kg twice a day for 5 days.</li><li>6 months to 5 years, 240 mg or 24 mg/kg twice a day for 5 days.</li><li>6 years to 11 years, 480 mg or 24 mg/kg twice a day for 5 days.</li></ul></li><li>For prophylaxis of a bite wound the dosage is as described above but prescribed for 3 days. </li></ul><!-- end field a15e2e76-e74f-4735-a333-a877009bd3eb --><!-- end item 065e82db-dcdc-4e25-ac56-a877009bd180 -->","subChapters":[]},{"id":"7d40a351-e860-527b-8e11-1d7bc54e46a5","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 17c14d46-ff22-4a0b-a0c4-a877009bfe54 --><h3>What are the contraindications and cautions when prescribing co-trimoxazole?</h3><!-- end field 17c14d46-ff22-4a0b-a0c4-a877009bfe54 -->","summary":"","htmlStringContent":"<!-- begin item 35d739e9-596e-4f1b-a8d9-a877009bfb58 --><!-- begin field be1164da-7698-45e3-b2f4-a877009bfe54 --><ul><li><strong>Do not prescribe co-trimoxazole in children:</strong><ul><li>With acute porphyrias.</li><li>With hypersensitivity to sulphonamides, trimethoprim, or co-trimoxazole.</li><li>With severe parenchymal hepatic disease.</li><li>In the first 6 weeks of life.</li><li>With severe renal insufficiency.</li><li>With previous drug induced thrombocytopaenia from use of trimethoprim and/or sulphonamides. </li></ul></li><li><strong>Prescribe co-trimoxazole with caution in children with:</strong><ul><li>Asthma or severe atopy.</li><li>Blood disorders (unless under specialist supervision).</li><li>G6PD deficiency (risk of haemolytic anaemia).</li><li>A predisposition to folate deficiency.</li><li>A predisposition to hyperkalaemia.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">BNF 74, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">ABPI, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">BNF for Children, 2020</a>]  </p><!-- end field be1164da-7698-45e3-b2f4-a877009bfe54 --><!-- end item 35d739e9-596e-4f1b-a8d9-a877009bfb58 -->","subChapters":[]},{"id":"749e141f-8d7f-5cdb-b9b5-a53ba0a4c8c0","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 50057fbe-5fe1-4029-8be3-a877009c2420 --><h3>What are the adverse effects of co-trimoxazole?</h3><!-- end field 50057fbe-5fe1-4029-8be3-a877009c2420 -->","summary":"","htmlStringContent":"<!-- begin item 7dbb16ca-5957-4bd6-ad2b-a877009c20f6 --><!-- begin field 98a572d0-c608-4a61-8ce8-a877009c2420 --><p>Common adverse effects of co-trimoxazole include diarrhoea, electrolyte imbalance, fungal overgrowth, headache, nausea, and skin reactions.</p><p>Less commonly it can cause vomiting. </p><p>Rare adverse effects include thromobocytopaenia and other blood disorders including leucopenia, megaloblastic anaemia, and eosinophilia. It can also cause a severe rash (including Stevens–Johnson syndrome or toxic epidermal necrolysis). It should be discontinued immediately if these adverse effects are caused. </p><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">BNF 74, 2017</a>]</p><!-- end field 98a572d0-c608-4a61-8ce8-a877009c2420 --><!-- end item 7dbb16ca-5957-4bd6-ad2b-a877009c20f6 -->","subChapters":[]},{"id":"e14647c0-cda5-5a0d-a66f-305a5e9910a6","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 6e10a6df-73a8-4df8-a03c-a877009c5173 --><h3>What drug interactions are associated with co-trimoxazole?</h3><!-- end field 6e10a6df-73a8-4df8-a03c-a877009c5173 -->","summary":"","htmlStringContent":"<!-- begin item 4267734d-ec0b-49b3-8be0-a877009c4d4a --><!-- begin field 5206026e-f314-4efd-a111-a877009c5173 --><p class=\"MsoNormal\"><strong>ACE inhibitors and angiotensin receptor blockers </strong>— caution should be exercised in patients taking any other drugs that can cause hyperkalaemia. Concomitant use of co-trimoxazole may result in hyperkalaemia.</p><p class=\"MsoNormal\"><strong>Azathioprine </strong>— there are conflicting clinical reports of interactions between azathioprine and trimethoprim-sulfamethoxazole, resulting in serious haematological abnormalities.</p><p class=\"MsoNormal\"><strong>Cyclosporin </strong>— reversible deterioration in renal function has been observed in patients treated with co-trimoxazole and cyclosporin following renal transplantation.</p><p class=\"MsoNormal\"><strong>Folinic acid </strong>— folinic acid supplementation has been shown to interfere with the antimicrobial efficacy of trimethoprim-sulfamethoxazole.</p><p class=\"MsoNormal\"><strong>Lamivudine </strong>— concomitant co-trimoxazole causes an increase in lamivudine exposure.</p><p class=\"MsoNormal\"><strong>Methotrexate </strong>— co-trimoxazole may increase the free plasma levels of methotrexate. If co-trimoxazole is considered appropriate therapy a folate supplement should be considered.</p><p class=\"MsoNormal\"><strong>Phenytoin </strong>— co-trimoxazole prolongs the half-life of phenytoin and if co-administered could result in excessive phenytoin effect. Close monitoring of the patient's condition and serum phenytoin levels are advisable.</p><p class=\"MsoNormal\"><strong>Pyrimethamine</strong> — occasional reports suggest that patients receiving pyrimethamine at doses in excess of 25 mg weekly may develop megaloblastic anaemia should co-trimoxazole be prescribed concurrently.</p><p class=\"MsoNormal\"><strong>Repaglinide</strong> — trimethoprim may increase the exposure of repaglinide which may result in hypoglycaemia.</p><p class=\"MsoNormal\"><strong>Spironolactone</strong> — caution should be exercised in patients taking any other drugs that can cause hyperkalaemia. Concomitant use of co-trimoxazole may result in hyperkalaemia.</p><p class=\"MsoNormal\"><strong>Sulfonylureas </strong>— interaction with co-trimoxazole is uncommon, but potentiation has been reported.</p><p class=\"MsoNormal\"><strong>Warfarin </strong>— co-trimoxazole has been shown to potentiate the anticoagulant activity of warfarin. Careful control of the anticoagulant therapy during treatment with co-trimoxazole is advisable.</p><p class=\"MsoNormal\"><strong>Zidovudine</strong> — in some situations, concomitant treatment with zidovudine may increase the risk of haematological adverse reactions to co-trimoxazole. If concomitant treatment is necessary, consideration should be given to monitoring of haematological parameters.</p><p class=\"MsoNormal\">[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">ABPI, 2020</a>]</p><!-- end field 5206026e-f314-4efd-a111-a877009c5173 --><!-- end item 4267734d-ec0b-49b3-8be0-a877009c4d4a -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}